Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Cash from Operations: 2011-2025

Historic Cash from Operations for Abeona Therapeutics (ABEO) over the last 14 years, with Sep 2025 value amounting to -$21.2 million.

  • Abeona Therapeutics' Cash from Operations fell 73.18% to -$21.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$74.9 million, marking a year-over-year decrease of 53.89%. This contributed to the annual value of -$56.0 million for FY2024, which is 51.36% down from last year.
  • According to the latest figures from Q3 2025, Abeona Therapeutics' Cash from Operations is -$21.2 million, which was down 12.79% from -$18.8 million recorded in Q2 2025.
  • Over the past 5 years, Abeona Therapeutics' Cash from Operations peaked at -$5.7 million during Q3 2023, and registered a low of -$30.3 million during Q4 2021.
  • Over the past 3 years, Abeona Therapeutics' median Cash from Operations value was -$12.7 million (recorded in 2024), while the average stood at -$13.8 million.
  • In the last 5 years, Abeona Therapeutics' Cash from Operations tumbled by 1,779.32% in 2021 and then surged by 53.76% in 2022.
  • Quarterly analysis of 5 years shows Abeona Therapeutics' Cash from Operations stood at -$30.3 million in 2021, then surged by 53.76% to -$14.0 million in 2022, then soared by 34.00% to -$9.2 million in 2023, then crashed by 79.31% to -$16.6 million in 2024, then slumped by 73.18% to -$21.2 million in 2025.
  • Its last three reported values are -$21.2 million in Q3 2025, -$18.8 million for Q2 2025, and -$18.4 million during Q1 2025.